Half-Life (Normalesrd) Hours
5 min/No data
Plasma Protein Binding %
No data
Volume Of Distribution L/Kg
0.2
Dose For Normal Renal Function
0.05 to 0.1 µg/kg/min
Second Dose
Second Dose: 0.05-0.3 µg/kg/min, titrate by 0.05-0.1 µg/kg/min q15min
Adjustment For Renal Failure Gfr, Ml/Min >50 [Recommended Level]
100% [D]
Adjustment For Renal Failure Gfr, Ml/Min 10-50 [Recommended Level]
100% [D]
Adjustment For Renal Failure Gfr, Ml/Min <10 [Recommended Level]
100% [D]
Supplement For Dialysis [Recommendation Level]: Ihd
IHD: None, [D]
Supplement For Dialysis [Recommendation Level]: Pd
PD: None, [D]
Supplement For Dialysis [Recommendation Level]: Crrt
CRRT: Dose for GFR 10-50, titrate, [D]
References
Brogden RN, Markham A. Fenoldopam: a review of its pharmacodynamic and pharmacokinetic properties and intravenous clinical potential in the management of hypertensive urgencies and emergencies. Drugs. 1997; 54: 634-50. [PMID: 9339965] / Taylor AA, Shepherd AM, Polvino W, Mangoo-Karim R, Ballard K, Sunthornyothin S, et al. Prolonged fenoldopam infusions in patients with mild to moderate hypertension: pharmacodynamic and pharmacokinetic effects. Am J Hypertens. 1999; 12: 906-14. [PMID: 10509549]
Toxicity Notes
Little is known about the effects of fenoldopam in renal insufficiency. Titrate based on blood pressure. No beneficial clinical effect on renal function has been shown in patients with heart failure or hepatic or severe renal disease.